Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Oncology at a glance [[electronic resource] /] / Graham G. Dark
| Oncology at a glance [[electronic resource] /] / Graham G. Dark |
| Autore | Dark Graham |
| Pubbl/distr/stampa | Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (138 p.) |
| Disciplina | 616.99/4 |
| Collana | At a glance |
| Soggetto topico |
Oncology - Methodology
Tumors - Diagnosis Tumors - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-118-27214-5
1-118-36970-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title page; Copyright page; Contents; Contributors; Preface; Abbreviations; 1: The global burden of cancer; The global burden of cancer; Developed and developing countries; Tobacco; Lifestyle; Infections; Challenges; 2: The nomenclature of oncology; Tumour nomenclature; Tumour grade; Cytology; Cytogenetic analysis; Tumour stage; Performance status; 3: Environmental determinants of cancer; Environmental factors; Radiation; Chemicals; Smoking; Infections; Hormones; Nutrition and lifestyle; 4: The hallmarks of cancer I; The 10 hallmarks of cancer; 1. Genome instability and mutation
2. Resisting cell death5: The hallmarks of cancer II; 3. Sustaining proliferative signalling; The cell cycle; Cell cycle regulation; Stimulation of the cell cycle; 4. Evading growth suppressors; 5. Enabling replicative immortality; 6: The hallmarks of cancer III; 6. Inducing angiogenesis; 7. Activating invasion and metastasis; 7: The hallmarks of cancer IV; 8. Reprogramming energy metabolism; 9. Tumour-promoting inflammation; 10. Evading immune destruction; 8: Cancer genetics and inherited cancer; Principles of cancer genetics; How genes cause cancer; Oncogenes; Tumour suppressor genes Multistep carcinogenesisInherited cancer syndromes; Autosomal dominant cancer syndromes; Autosomal recessive cancer syndromes; 9: Communicating with cancer patients; Communicating with cancer patients; The doctor-patient relationship; Breaking bad news; Steps to breaking bad news; Dealing with the emotional patient; Communicating with younger patients; 10: Presenting problems in a patient with cancer; Presenting features of cancer; General features on examination; Local effects; Change of function; Obstruction of a conduit; Metastatic effects; 11: Paraneoplastic syndromes Ectopic hormone productionNeurological manifestations; Cutaneous manifestations; Haematological manifestations; Gastrointestinal manifestations; Renal manifestations; Other paraneoplastic syndromes; 12: Metabolic emergencies in cancer patients; Hypercalcaemia; Syndrome of inappropriate antidiuresis; Hypomagnesaemia; Tumour lysis syndrome; 13: Oncological emergencies; Neutropenic sepsis; Superior vena cava obstruction; Spinal cord compression; 14: Investigation and management of metastatic disease; Brain metastases; Lung metastases; Liver metastases; Bone metastases; Malignant pleural effusion Malignant ascitesOther sites; 15: Tumour markers; Serum proteins; Clinical usefulness; Human chorionic gonadotrophin; Alpha-fetoprotein; Placental alkaline phosphatase; CA19-9; Inhibin; Carcinoembryonic antigen (CEA); CA15-3; CA125; Squamous cell carcinoma-associated antigen (SCC); Prostate-specific antigen (PSA); Hormones; 16: Screening for cancer; Successful screening; Lead time bias; Length time bias; Breast cancer screening; Colorectal cancer screening; Gastric cancer screening; Prostate cancer screening; Cervical cancer screening; Ovarian cancer screening; Lung cancer screening The future |
| Record Nr. | UNINA-9910465114403321 |
Dark Graham
|
||
| Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oncology at a glance [[electronic resource] /] / Graham G. Dark
| Oncology at a glance [[electronic resource] /] / Graham G. Dark |
| Autore | Dark Graham |
| Pubbl/distr/stampa | Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (132 pages) : illustrations |
| Disciplina | 616.99/4 |
| Collana | At a glance |
| Soggetto topico |
Oncology - Methodology
Tumors - Diagnosis Tumors - Treatment |
| ISBN |
111836970X
9781118369708 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910795825903321 |
|
Dark Graham
|
||
| Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oncology at a glance / / Graham G. Dark
| Oncology at a glance / / Graham G. Dark |
| Autore | Dark Graham |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (132 pages) : illustrations |
| Disciplina | 616.99/4 |
| Collana | At a glance |
| Soggetto topico |
Oncology - Methodology
Tumors - Diagnosis Tumors - Treatment |
| ISBN |
9781118369708
111836970X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title page -- Copyright page -- Contents -- Contributors -- Preface -- Abbreviations -- 1: The global burden of cancer -- The global burden of cancer -- Developed and developing countries -- Tobacco -- Lifestyle -- Infections -- Challenges -- 2: The nomenclature of oncology -- Tumour nomenclature -- Tumour grade -- Cytology -- Cytogenetic analysis -- Tumour stage -- Performance status -- 3: Environmental determinants of cancer -- Environmental factors -- Radiation -- Chemicals -- Smoking -- Infections -- Hormones -- Nutrition and lifestyle -- 4: The hallmarks of cancer I -- The 10 hallmarks of cancer -- 1. Genome instability and mutation -- 2. Resisting cell death -- 5: The hallmarks of cancer II -- 3. Sustaining proliferative signalling -- The cell cycle -- Cell cycle regulation -- Stimulation of the cell cycle -- 4. Evading growth suppressors -- 5. Enabling replicative immortality -- 6: The hallmarks of cancer III -- 6. Inducing angiogenesis -- 7. Activating invasion and metastasis -- 7: The hallmarks of cancer IV -- 8. Reprogramming energy metabolism -- 9. Tumour-promoting inflammation -- 10. Evading immune destruction -- 8: Cancer genetics and inherited cancer -- Principles of cancer genetics -- How genes cause cancer -- Oncogenes -- Tumour suppressor genes -- Multistep carcinogenesis -- Inherited cancer syndromes -- Autosomal dominant cancer syndromes -- Autosomal recessive cancer syndromes -- 9: Communicating with cancer patients -- Communicating with cancer patients -- The doctor-patient relationship -- Breaking bad news -- Steps to breaking bad news -- Dealing with the emotional patient -- Communicating with younger patients -- 10: Presenting problems in a patient with cancer -- Presenting features of cancer -- General features on examination -- Local effects -- Change of function -- Obstruction of a conduit -- Metastatic effects.
11: Paraneoplastic syndromes -- Ectopic hormone production -- Neurological manifestations -- Cutaneous manifestations -- Haematological manifestations -- Gastrointestinal manifestations -- Renal manifestations -- Other paraneoplastic syndromes -- 12: Metabolic emergencies in cancer patients -- Hypercalcaemia -- Syndrome of inappropriate antidiuresis -- Hypomagnesaemia -- Tumour lysis syndrome -- 13: Oncological emergencies -- Neutropenic sepsis -- Superior vena cava obstruction -- Spinal cord compression -- 14: Investigation and management of metastatic disease -- Brain metastases -- Lung metastases -- Liver metastases -- Bone metastases -- Malignant pleural effusion -- Malignant ascites -- Other sites -- 15: Tumour markers -- Serum proteins -- Clinical usefulness -- Human chorionic gonadotrophin -- Alpha-fetoprotein -- Placental alkaline phosphatase -- CA19-9 -- Inhibin -- Carcinoembryonic antigen (CEA) -- CA15-3 -- CA125 -- Squamous cell carcinoma-associated antigen (SCC) -- Prostate-specific antigen (PSA) -- Hormones -- 16: Screening for cancer -- Successful screening -- Lead time bias -- Length time bias -- Breast cancer screening -- Colorectal cancer screening -- Gastric cancer screening -- Prostate cancer screening -- Cervical cancer screening -- Ovarian cancer screening -- Lung cancer screening -- The future -- 17: Imaging in oncology -- Plain film imaging -- Ultrasound -- Computerised tomography -- Magnetic resonance imaging -- Radioisotope imaging -- Positron emission tomography -- 18: Approach to treatment and response assessment -- Treatment goals -- Treatment approach -- Assessment of toxicity -- Evaluation of treatment -- 19: Principles of surgical oncology -- Surgical oncology -- Prevention -- Evaluation of primary disease -- Biopsy types -- Staging -- Treatment -- Palliative procedures -- 20: Pharmacology of anticancer agents. An introduction to chemotherapy -- Growth fractions and doubling time -- Tumour growth -- Drug resistance -- Class of chemotherapy agents -- 21: Principles of radiotherapy -- How radiotherapy works -- High-energy photons -- Photoelectric effect -- Compton effect -- Pair production -- Types of radiation treatment -- Electron beams -- Brachytherapy -- Conformal radiation therapy -- Intensity-modulated radiation therapy (IMRT) -- Proton therapy -- Stereotactic radiosurgery -- 22: Adverse effects of treatment -- Treatment toxicity -- Extravasation injury -- Specific toxicities -- Late adverse effects -- 23: Management of nausea -- Pathophysiology -- Oncology practice -- Approach to treatment -- Patients with advanced disease -- 24: Analgesia -- Pain assessment -- Treatment -- Opioid analgesia -- Side effects -- 25: Clinical trials in cancer patients -- Asking a research question -- Observational studies -- Phase I clinical trials -- Phase II clinical trials -- Phase III clinical trials -- Randomisation -- Meta-analysis -- 26: The role of multidisciplinary teams -- Multidisciplinary team meetings -- Role of the team -- Benefit of MDT meetings -- Combined clinics -- Recruitment into clinical trials -- Education opportunities -- 27: End of life care -- Physical symptoms -- Psychological issues -- Managing the terminal phase -- 28: Carcinoma of unknown primary -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Initial investigations -- Treatment -- Prognosis -- 29: Breast cancer -- Epidemiology -- Aetiology and pathophysiology -- Clinical presentation -- Treatment -- Prevention -- Screening -- 30: Lung cancer -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- 31: Mesothelioma -- Epidemiology -- Aetiology -- Clinical presentation. Investigations and staging -- Treatment -- Prognosis -- 32: Oesophageal cancer -- Epidemiology -- Aetiology and pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 33: Gastric cancer -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 34: Colorectal cancer -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- Screening -- 35: Pancreatic cancer -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Staging -- Treatment -- Prognosis -- 36: Hepatobiliary cancer -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 37: Ovarian cancer -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigation and staging -- Treatment -- Complications -- Prognosis -- 38: Endometrial cancer -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Treatment -- Complications -- Prognosis -- 39: Cervical cancer -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Screening -- Screening following treatment -- Treatment -- Prognosis -- 40: Germ cell tumours -- Epidemiology -- Aetiology -- Pathophysiology -- Seminoma and dysgerminoma -- Non-seminoma -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 41: Prostate cancer -- Epidemiology -- Aetiology and pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Screening -- Prognosis -- 42: Bladder and renal cancer -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Bladder cancer -- Renal cancer -- Prognosis -- 43: Head and neck cancer. Epidemiology -- Aetiology -- Pathophysiology -- Clinical examination -- Investigations and staging -- Treatment -- Prognosis -- 44: Thyroid cancer -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 45: Bone cancer and sarcoma -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 46: Skin cancer -- Epidemiology -- Aetiology -- Non-melanoma skin cancer -- Basal cell carcinoma -- Squamous cell carcinoma -- Melanoma -- 47: Cancers of the central nervous system -- Epidemiology -- Aetiology -- Clinical presentation -- Glial tumours -- Meningioma -- Spinal axis tumours -- Investigations and staging -- Treatment -- Complications -- Prognosis -- 48: Neuroendocrine tumours -- Argentaffin and hormone secretion -- Carcinoid tumours -- Gastroenteropancreatic NETs -- Insulinoma -- Gastrinoma -- Glucagonoma -- VIPoma -- Somatostatinoma -- Phaeochromocytoma -- Serum tumour markers -- 49: Leukaemia -- Epidemiology and pathogenesis -- Clinical presentation -- Investigations and classification -- Treatment -- Prognosis -- 50: Hodgkin's lymphoma -- Epidemiology -- Aetiology -- Pathophysiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 51: Non-Hodgkin's lymphoma -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 52: Myeloma -- Epidemiology -- Aetiology -- Clinical presentation -- Investigations and staging -- Treatment -- Prognosis -- 53: Childhood cancers -- Paediatric oncology -- Teenager and young adult oncology -- Aetiology -- Haematological cancers -- Leukaemia -- Lymphoma -- Embryonal tumours -- Neuroblastoma -- Retinoblastoma -- Nephroblastoma (Wilm's tumour) -- Hepatoblastoma -- Central nervous system cancer -- Glioma. Intracranial and intraspinal embryonal tumours. |
| Record Nr. | UNINA-9910958372903321 |
|
Dark Graham
|
||
| Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||